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M A J O R A R T I C L E
Pregnancy and Fetal Outcomes After Exposure to
Mefloquine in the Pre- and Periconception
Period and During Pregnancy
Patricia Schlagenhauf,1 William A. Blumentals,2 Pia Suter,2 Loredana Regep,2 Gabriel Vital-Durand,2
Martin T. Schaerer,2 Margarita Suarez Boutros,2 Hans-Georg Rhein,2 and Miriam Adamcova2
1Division of Epidemiology and Communicable Diseases, University of Zurich Centre for Travel Medicine, Institute for Social and Preventive Medicine,
Zurich, Switzerland; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background. Pregnant women who travel to malarious areas and their clinicians need data on the safety of
malaria chemoprophylaxis.
Methods. The effect of exposure to mefloquine on pregnancy and offspring outcomes was evaluated using
the F. Hoffmann–La Roche global drug safety database for the time frame 31 January 1986 through 26 October 2010.
We investigated pregnancy and fetal outcomes in maternal, paternal, and both-parent exposure cases with a focus
on congenital malformations and fetal loss. The main outcome measures were birth defect prevalence and types
of malformations.
Results. A total of 2506 cases of mefloquine exposure during pregnancy or in the pre- and periconception
period were evaluated. Most cases were maternal prospective (outcome of the pregnancy unknown at the time of
reporting; n 5 2246 [89.6%]) followed by maternal retrospective cases (outcome of the pregnancy known at the
time of reporting; n 5 227 [9.0%]), with small numbers of paternal and both-parent exposure cases. Of the total
2246 mefloquine maternal prospective exposures (95.2%), 2139 occurred before conception and/or during the first
trimester. Of 1383 maternal prospective cases with known outcome, 978 (70.7%) resulted in delivery, 405 (29.3%)
resulted in abortion (112 spontaneous, 293 therapeutic), and 43 resulted in birth defects, corresponding to a birth
defect prevalence of 4.39% (43 of 978). Prospective cases overall showed no specific pattern of birth malformations.
Conclusions. The drug safety database analysis of mefloquine exposure in pregnancy showed that the birth
defect prevalence and fetal loss in maternal, prospectively monitored cases were comparable to background rates.
An estimated 80–90 million travelers visit malaria-
endemic areas annually [1], and a significant proportion
of these are women of childbearing potential. Malaria
during pregnancy poses a significant risk to the mother,
the fetus, and the neonate [2–4]. Malaria infection
should be prevented if possible. Women who have
little or no immunity, such as nonimmune travelers,
are particularly prone to episodes of severe malaria
with outcomes such as stillbirth, spontaneous abortion,
or maternal death [3–5], which are probably due to high
maternal fever leading to uterine contractions.
Travelers to high-risk areas of chloroquine-resistant
Plasmodium falciparum need protective measures.
Personal protection against mosquito bites is a key
strategy, and a combination of insecticide-treated bed
nets [6, 7] and DEET repellents is considered safe
during pregnancy [5–8]. The efficacy of such meas-
ures for travelers is difficult to quantify [9], and most
women at high risk also need chemoprophylaxis.
Based on experience, chloroquine is considered safe
to use during pregnancy [10]. However, because of
resistance, this regimen has limited applicability.
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Doxycycline is generally contraindicated in pregnancy [11]. Some
experts suggest that doxycycline use may be acceptable in early
pregnancy, but data are limited [12]. Owing to insufficient data,
the atovaquone-proguanil combination is not recom-
mended, although the 2 components are not considered
teratogenic. Thus, for ethical, safety, and logistical reasons,
there is a lack of data on the use of antimalarials by pregnant
women [13].
Mefloquine has been available to travelers since 1985. It is
recommended for pregnant women who travel to chloroquine-
resistant P. falciparum areas when travel cannot be deferred.
The recommendations made by expert groups worldwide
have been reviewed recently [14]. Expert recommendations
data are needed to support clinical decisions. The US and
Canadian guidelines allow the use of mefloquine chemo-
prophylaxis in all trimesters when travel cannot be deferred,
with no recommendation regarding contraception for the
3 months after the use of mefloquine. The international
standard prescribing information, the World Health Orga-
nization, and the UK authorities sanction the use of me-
floquine when there is travel to a high-risk malaria area but
are more restrictive in the first trimester and also recom-
mend contraception for 3 months after use. All authorities
agree that inadvertent use of mefloquine during pregnancy
is not viewed as an indication to terminate a pregnancy.
Many authorities recommend a benefit-risk analysis before
prescribing mefloquine for pregnant women, particularly
in the first trimester. Practitioners need up-to-date evidence
to guide this decision making. Consequently, we conducted
the present analysis using a drug safety database to in-
vestigate the safety for the fetus following exposure to me-
floquine (as Lariam) in the periconception period and
during pregnancy.
METHODS
All serious adverse events from clinical trials of mefloquine
and all spontaneous reports of adverse events are coded and
entered into the F. Hoffmann–La Roche global drug safety
database. Events were classified using the standardized
Medical Dictionary for Regulatory Activities (MedDRA ver-
sion 13.1). All reports entered from 31 January 1986 to the
cutoff date of 26 October 2010 and marked as ‘‘pregnancy’’
were retrieved and evaluated. Summary cases (ie, reports
mentioning several pregnancies without the possibility to
identify individuals) were excluded from the analysis as
standard procedure. Maternal exposure, paternal exposure,
and both-parent exposure were separately analyzed.
Pregnancy reports were either prospective (outcome of the
pregnancy unknown at the time of first reporting) or, less
often, retrospective (outcome of the pregnancy known at
the time of first reporting). These 2 groups were separately
evaluated. Pregnancy and fetal outcomes were stratified
by exposure trimester. The exposure periods evaluated were
pre- and periconception and the first, second, and third
trimesters. We focused on congenital malformations after
exposure to mefloquine based on maternal prospective re-
ports. Pregnancy outcomes were categorized as follows: de-
livery, abortion (spontaneous, therapeutic), and unknown.
Fetal outcomes were: birth defect, normal infant or normal
fetus, other disorder, and unknown. The term ‘‘birth defect’’
or ‘‘birth malformation,’’ as used by the March of Dimes,
refers to congenital anomalies identified by codes 740–759 of
the International Classification of Diseases, Ninth Revision
(ICD-9) [15]. Using US federal documentation, we defined
a pregnancy outcome of fetal death before 20 completed
weeks of gestation as a ‘‘spontaneous abortion.’’ After
20 weeks, fetal death was termed ‘‘stillbirth’’ [16]. The term
‘‘teratogen’’ was defined as a drug that may have the potential
to cause developmental toxicity given the appropriate con-
ditions at clinical doses used in humans [16]. The prevalence
of birth defects and the occurrence of fetal loss in the ma-
ternal prospective cases exposed to mefloquine were com-
pared with the background rates in the general population,
as published by various databases. Birth malformations
in maternal prospective cases including deliveries and
abortions were divided into subgroups based on ICD-10,
chapter XVII, ‘‘Congenital malformations, deformations and
chromosomal abnormalities,’’ and compared with categories
of birth defects from the March of Dimes [16].
RESULTS
A total of 2506 cases of mefloquine exposure during preg-
nancy or in the periconception period were evaluated. The
reports originated primarily from France (n 5 783), the
United Kingdom (n 5 661), Germany (n 5 645), and
the United States (n 5 138), with peak reporting from 1994
to 1998. Most cases (n 5 2477; 98.8%) were reported
spontaneously; a small number of reports came from the
literature (n 5 26; 1.0%) or from clinical studies (n 5 3;
0.1%). Most cases were reported by health professionals
(n 5 2287; 91.3%), followed by consumers (n 5 103; 4.1%)
and regulatory authorities (n 5 36; 1.4%). The mean age
was 29 years for the maternal prospective cases (range,
15–52 years; median, 29 years) and 30 years for the maternal
retrospective cases (range, 19–45 years; median, 30 years).
The majority of cases were maternal prospective
(n 5 2246; 89.6%; Tables 1 and 2) followed by maternal
retrospective cases (n 5 227; 9%; Tables 3 and 4) and small
numbers of paternal (5 prospective, 4 retrospective) and
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both-parent (22 prospective, 2 retrospective) exposure cases.
Most women exposed to mefloquine were using the drug for
malaria chemoprophylaxis. Treatment doses were recorded for
21 maternal prospective and 12 maternal retrospective cases.
Of the 2246 maternal prospective cases, 1383 with known
pregnancy outcome resulted in 978 deliveries with 43 birth
defects, 43 other pregnancy-related or perinatal disorders,
and 889 normal infants. This corresponds to a birth prevalence
of 4.39% congenital malformations (43 of 978 births).
Twelve women who delivered infants with birth defects had
a medical history of drug abuse (n 5 1), alcohol use (n 5 1),
hypothyroidism (n 5 1), hepatitis B (n 5 1), smoking (n 5 2),
preeclampsia (n 5 1), spontaneous abortions (n 5 2), previous
miscarriages (n 5 2), and family history of epilepsy or other
unspecified mental handicap (n 5 1). Six of these 43 women
had no relevant medical history, and the medical history of
the majority of women (n 5 25) who gave birth to infants
with birth malformations was unknown. All but 2 of these
43 women received 250 mg mefloquine weekly. The duration
of mefloquine use was between 6 and 91 days.
With regard to the time of exposure, 2139 of the 2246
mefloquine maternal prospective exposures (95.2%) oc-
curred before conception and/or during the first trimester of
pregnancy (Table 4). All congenital malformations occurred
in infants of women who had taken mefloquine during this
period of exposure (Table 2).
Table 1. Pregnancy Outcomes in Maternal Prospective Cases (n 5 2246)
Pregnancy Outcome
Offspring Status Total
Birth
Defect
Unavailable for
Follow-upa
Normal
Infant
Normal
Fetus
Other
Disorderb
Pregnancy
Ongoinga Unknowna No. %
Delivery 43 0 889 0 43 0 3 978 43.5
Unavailable for follow-upc 0 434 0 0 0 0 6 440 19.6
Pregnancy ongoingc 0 1 0 0 0 6 0 7 0.3
Spontaneous abortion 1 1 0 3 6 0 101 112 5.0
Therapeutic abortion 8 0 0 1 6 0 278 293 13.0
Unknownc 1 0 0 0 1 365 49 416 18.5
Total 53 436 889 4 56 371 437 2246 100.0
Of the 2246 women, 221 were white, 22 were black, 6 were Asian, and 12 were reportedly of ‘‘other’’ ethnic origin; for the majority of women (1985 of 2246), ethnic
origin was unknown.
a Fetal outcomes were unknown in these groups (pregnancy ongoing, unavailable for follow-up, and unknown).
b Fifty-six maternal prospective cases of other disorders with 78 events included various adverse events related to the pregnancy and delivery. The most frequently
reported were neonatal jaundice (n 5 12), premature delivery (n 5 8), placental disorder (n 5 8), fetal growth restriction (n 5 6), small-for-dates infant (n 5 4), fetal
distress syndrome (n 5 4), stillbirth or intrauterine death (n 5 3), bradycardia (n 5 2), blighted ovum (n 5 2), unspecified neonatal disorder (n 5 2), and neonatal
asphyxia (n5 2). The rest of the ‘‘other disorders’’ data set (n5 25) included different pregnancy- and delivery-related reported terms, n5 1 for each reported item.
c Pregnancy outcomes unknown (pregnancy ongoing, unavailable for follow-up and outcome unknown).
Table 2. Offspring Status According to Period of Mefloquine Exposure in Maternal Prospective Cases (n 5 2246)
Time of Exposure
for Mother
Offspring Status Total
Birth
Defect
Unavailable for
Follow-up
Normal
Infant
Normal
Fetus
Other
Disorder
Pregnancy
Ongoing Unknown No. %
Trimester 1 16 174 297 1 21 122 177 808 36.0
Trimesters 1 1 2 1 0 7 0 2 3 1 14 0.6
Trimesters 1 1 3 0 1 0 0 0 0 0 1 0.0
Trimesters 1–3 0 0 3 0 0 0 1 4 0.2
Trimester 2 0 1 3 0 0 4 1 9 0.4
Trimester 3 0 0 1 0 0 1 1 3 0.1
Before 15 113 240 0 15 102 107 592 26.4
Before 1 trimesters 1 1 2 0 1 0 0 0 0 0 1 0.0
Before 1 trimester 1 21 131 328 3 17 102 137 739 32.9
Before 1 trimester 3 0 0 1 0 0 0 0 1 0.0
Unknown 0 15 9 0 1 37 12 74 3.3
Total 53 436 889 4 56 371 437 2246 100.0
d d Schlagenhauf et alCID 2012:54 (1 June)e126
In the majority of spontaneous and therapeutic abortions,
the offspring status was unknown. Three of the 8 women
who underwent therapeutic abortion and had a fetus with
birth defects had a medical history of toxoplasmosis (n5 1),
ectopic pregnancy (n5 1), or induced abortion (n 5 1); 1 of
the 8 had no relevant medical history. All received 250 mg
mefloquine weekly for 1–50 days. There was 1 birth defect in
the spontaneous abortion group (1 of 112 pregnancies) and
1 in the unknown-outcome group (1 of 416 pregnancies). Six
of these 10 cases did not include details on medical history.
Three prospective stillbirth cases were identified; 1 case was
coded as ‘‘stillbirth,’’ and 2 as ‘‘intrauterine death.’’ The first
included narrative referring to stillbirth and death due to
toxoplasmosis; the second included placental hypoplasia
with maturation dissociation of villi and Endangiopathia
obliterans.
Of 22 prospective both-parent exposure cases, 14 (63.6%)
resulted in delivery and 1 (4.5%) in spontaneous abortion.
The 14 deliveries resulted in 2 birth defects and 12 normal
infants; no other pregnancy-related or perinatal disorder was
reported. One of 2 women who gave birth to infants with
birth defects was a tobacco user and had taken 250 mg me-
floquine weekly for 19 days; the other received the same dose
for 50 days and her medical history was unknown. As in the
maternal prospective cases, 2 birth defects occurred in pro-
spective cases of both-parent exposure (after mefloquine
use) in the periconception period and during the first tri-
mester. The spectrum of birth defects reported in all pro-
spective cases was divided into 10 subcategories (Table 5).
There was no specific pattern of malformations.
DISCUSSION
Pregnant women traveling to chloroquine-resistant P. falciparum
malaria-endemic areas need malaria prophylaxis. In addition,
women who use mefloquine prophylaxis may experience
unplanned pregnancy and need advice on the safety of the
prescribed antimalarial drug, particularly with regard to its
teratogenic potential in the periconception and first-trimester
periods, and information on fetal loss (spontaneous abortion
Table 3. Pregnancy Outcomes in Maternal Retrospective Cases (n 5 227)
Pregnancy Outcome
Offspring Status Total
Birth
Defect
Unavailable for
Follow-up
Normal
Infant
Normal
Fetus
Other
Disorder
Pregnancy
Ongoing Unknown No. %
Delivery 30a 1 98 0 11 0 1 141 62.1
Pregnancy ongoing 0 0 0 0 0 1 0 1 0.4
Spontaneous abortion 1 0 0 3 3 0 31 38 16.7
Therapeutic abortion 19 0 0 1 4 0 17 41 18.1
Unknown 2 0 1 0 0 3 0 6 2.6
Total 52 1 99 4 18 4 49 227 100.0
a Includes 1 stillbirth with Patau syndrome (trisomy 13).
Table 4. Offspring Status According to Period of Mefloquine Exposure in Maternal Retrospective Cases (n 5 227)
Time of Exposure
for Mother
Offspring Status Total
Birth
Defect
Unavailable for
Follow-up
Normal
Infant
Normal
Fetus
Other
Disorder
Pregnancy
Ongoing Unknown No. %
Trimester 1 21 1 35 3 5 2 13 80 35.2
Trimesters 1 1 2 1 0 4 0 0 0 0 5 2.2
Trimesters 1–3 0 0 1 0 0 0 0 1 0.4
Trimester 2 2 0 2 0 0 1 0 5 2.2
Trimesters 2 1 3 1 0 0 0 1 0 0 2 0.9
Trimester 3 2 0 1 0 0 0 0 3 1.3
Before 13 0 22 0 2 0 10 47 20.7
Before 1 trimesters 1–3 0 0 1 0 0 0 0 1 0.4
Before 1 trimester 1 7 0 29 1 7 0 20 64 28.2
Unknown 5 0 4 0 3 1 6 19 8.4
Total 52 1 99 4 18 4 49 227 100.0
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and stillbirth). It is important that available data on drug
exposure during pregnancy be routinely reviewed to enable
evidence-based decision making. Furthermore, new policy
decisions on use of mefloquine in pregnancy will be influ-
enced by data on the safety of mefloquine in pregnancy. This
is currently of particular importance as it relates to global
health because mefloquine is a potential partner drug in
artemisinin combination treatments that will be recom-
mended in pregnancy or for women of childbearing potential
in endemic areas.
The drug safety database analysis showed an overall birth
prevalence of 4.39% of congenital malformations in mater-
nal prospective cases, with no specific pattern of malfor-
mations. The exposure period of 95.3% of these maternal
cases was periconception and the first trimester. To assess
whether the use of a drug might be associated with an in-
creased prevalence of birth malformations, the rate of birth
defects found in the database analysis should be compared
with the background rates in the general population, using
various birth defect databases. The prevalence of congenital
malformations in the general population varied by country,
pregnancy registry, and year of reporting. According to the
March of Dimes [15], approximately 4% of infants annually
(1/28) are born with a major birth defect or congenital
malformation, for which the etiology is largely unknown
[16–18]. European Surveillance of Congenital Anomalies
reported a 2.37% total prevalence of major congenital
anomalies in the years 2000–2004 [19]. Older publications
report a prevalence of congenital malformations of between
0.8% and 6.5% [20].
The grouping of birth defects in our study was similar to
the leading categories of birth defects in the general pop-
ulation as published by the March of Dimes and the Food
and Drug Administration [15, 16]. There was no specific
pattern of malformations in our study. The leading catego-
ries of musculoskeletal (11 of 978, 1.1%; 95% confidence
interval [CI], .6%–2.0%]), urogenital (11 of 978; 1.1%; 95%
CI, .6%–2.0%), and circulatory (8 of 978; 0.8%; 95% CI,
.4%–1.16%) were comparable to findings in general pop-
ulation databases. Six of the prospective birth defects in
our study were chromosomal abnormalities, which are usu-
ally genetic in origin and therefore probably not caused
by mefloquine.
For a large proportion of the prospective spontaneous
and therapeutic abortions (,20 weeks postconception), the
offspring status was unknown, which precluded additional
detailed analysis. Among cases with known offspring status,
most were in the therapeutic abortion group (8 of 293). The
prevalence of therapeutic abortions with confirmed birth
defects in all prospective cases in our analysis was compa-
rable to the background rate of induced abortions in the
general population reported in the literature [19]. We ob-
served 3 stillbirths with other disorders, which was compa-
rable to the background rate in the general population [21].
Our analysis has some limitations. We did not have
a control group and instead compared our data with avail-
able literature and other database sources, which is consid-
ered weaker evidence than a controlled study. All observed
differences in birth defects in the comparator databases
could occur frequently as a result of sampling variation,
Table 5. Characteristics of Birth Defects and Associated Pregnancy-Related and Perinatal Disorders Reported in All Prospective Cases
Location
Maternal Exposure
(53 Prospective
Cases, 70 Events)a
Paternal
Exposure,
(No Prospective Cases)
Both-Parent Exposure,
(3 Prospective
Cases, 4 Events)
Nervous system 5 0 0
Eye, ear, face, and neck 8 0 0
Digestive system 3 0 0
Circulatory system 8 0 1
Urinary, genital organs 11 0 2
Musculoskeletal system 11 0 0
Chromosomal abnormalities 6 0 0
Multiple 1 0 0
Other pregnancy related
disorders and not otherwise specifiedb
17 0 1
Total 70 0 4
a Cases may have more than one event.
b Seventeen other pregnancy-related events such as fetal growth restriction, neonatal hyperbilirubinemia, hypoglycemia, neonatal jaundice, polycythemia,
premature infant, congenital pneumonia, unspecified congenital cysts, dermoid cysts, congenital hernia, intrauterine death, induced abortion, imminent abortion,
and sacral skin dimple were reported in association with these malformations.
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coding, baseline factors, follow-up completeness, reporting
years, regions, countries, environment, socioeconomic sta-
tus, or lifestyle and may not represent true differences
between the proportions of infants with birth defects in the
comparison groups. A further limitation is underreporting.
We focused on prospective cases, but data were available on
fetal outcome in just 44.6% of the cases in our study, despite
several attempts at follow-up. We also list data on retro-
spective cases (Tables 3 and 4), but these cases are not dis-
cussed in detail because retrospective reporting is known to
be associated with bias and must be interpreted with caution.
A mother of an infant born with a major birth defect may be
more likely to recall gestational exposures than the mother
of a normal infant. This is a recognized phenomenon in
retrospective reporting. For example, Bar-Oz et al found that
the rate of congenital malformations after first-trimester
exposure to itraconazole was 4 times higher when ascer-
tained retrospectively rather than prospectively [22]. Fur-
thermore, our analysis does not have the power to detect
abnormal outcomes that occur at relatively low background
rates or rare abnormalities, and the issues of long-term social
or functional development cannot be monitored.
The strength of our evaluation is its focus on the target
group and detailed scrutiny of the evidence of mefloquine
use in this group using a global drug safety database. To the
best of our knowledge, ours is the largest source of in-
formation currently available to study the use of mefloquine.
Most exposures documented here occurred in the peri-
conception and first-trimester periods, a critical time for the
fetus because first-trimester exposure is generally associated
with an increased rate of occurrence of malformations [18].
Mefloquine is known to cross the placenta and it has a long
half-life, which ranges from 2 to 4 weeks, with an average of
3 weeks.
Because no single approach can delineate the entire
spectrum of outcomes associated with drug exposure during
pregnancy and to put our research into context, we screened
all available literature on the use of mefloquine chemopro-
phylaxis in pregnancy using the search terms ‘‘mefloquine,’’
‘‘prophylaxis,’’ and ‘‘pregnancy.’’ Our current evaluation sup-
ports the results of an earlier postmarketing data evaluation
that had a data cutoff date of 10 September 1996 and showed
no increase in congenital malformations in 1526 mefloquine-
exposed women (4%) over the expected background rate [23].
Other literature includes early animal studies with me-
floquine, which provide only weak evidence and cannot be
extrapolated to humans. Teratogenic and embryotoxic ef-
fects of mefloquine in these animal studies were observed
after administration of doses usually in excess of 100 mg/kg.
In comparison, the dose of mefloquine chemoprophylaxis
for women is 5 mg/kg once weekly.
The issue of fetal loss as ‘‘spontaneous abortion’’ or
‘‘stillbirth’’ in mefloquine-exposed mothers is important.
In the 2246 maternal prospective cases, 112 spontaneous
abortions were reported (5%), and 3 stillbirths. This is
comparable to background rates in the general population,
where 1 in 7 (16%) pregnancies result in spontaneous
abortion and 1 in 200 result in stillbirth [16]. A large study in
Denmark showed that the risk of spontaneous abortion in
women aged 20–24 years was 8.9%, increasing with age to
74.7% in women aged $45 years [24]. The mean age of
women in our maternal prospective cases was 29 years
(range, 15–52 years; median, 29 years).
We also scrutinized the literature on the use of mefloquine
in pregnant women [25]. Although the scope of this article
is limited to mefloquine prophylaxis use in nonimmune
travelers, 3 important relevant studies of mefloquine pro-
phylaxis in semi-immune pregnant women warrant mention
here. The first study was in 339 semi-immune pregnant Thai
women (.20 weeks of gestation), and mefloquine pro-
phylaxis was well tolerated [26]. No significant adverse im-
pact was observed on the mother, course of pregnancy,
infant survival, or infant development (up to age 2 years).
A higher overall rate of stillbirths was noted for mefloquine users
(11 in 159 vs 4 in 152 for placebo). The authors concluded that
mefloquine was safe and effective for antimalarial prophylaxis
in the second half of pregnancy [26].
The second study [27, 28] in malaria chemoprophylaxis and
treatment involved semi-immune women in the Mangochi
District of Malawi. The study showed no significant differ-
ences in the frequency of abortions or stillbirths in women
receiving chloroquine (n 5 3077) or mefloquine (n 5 1032)
prophylaxis during the second and third trimesters.
A third study investigating the pharmacokinetics of me-
floquine prophylaxis in 20 semi-immune women in the third
trimester of pregnancy found no abnormalities in offspring
who were followed up until 2 years of age [29]. This study
showed increased clearance of mefloquine in late pregnancy,
with implications for an increased chemoprophylaxis dosage
in the third trimester.
All other studies focused on nonimmune women who
used mefloquine during travel. In 1 evaluation of malaria
chemoprophylaxis [30], 331 women exposed to mefloquine
were compared with 153 women exposed to sulfadoxine-
pyrimethamine. Fetal anomalies were lower in the mefloquine
group (4.8%) than in the sulfadoxine-pyrimethamine group
(7.8%). However, the mefloquine group had a significantly
higher proportion of spontaneous abortions (9.1% vs 2.6%),
although this was still within the background rate for the
population studied.
Additional data on the use of mefloquine chemoprophylaxis
in nonimmune pregnant women came from a case series of
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10 women exposed in the first trimester of pregnancy [31]
(without malformations). Further data are published on US
servicewomen [32] who inadvertently used mefloquine prior
to becoming aware of their pregnancy during military op-
erations. They had a high rate of spontaneous abortions,
which was attributed to stressors in the combat environment.
In 23 live births, there were no congenital malformations.
CONCLUSIONS
In summary, the prospective data shown here suggest that
fetal loss and the birth prevalence of malformations (4.39%)
in mefloquine-exposed mothers were comparable to back-
ground levels in the general population. No specific pattern
of malformations was identified. This evidence corroborates
the recommendation that inadvertent use of mefloquine
in pregnancy does not constitute grounds for therapeutic
abortions and provides guidance for women and their
clinicians regarding the use of mefloquine prophylaxis in the
pre- and periconception periods and during pregnancy.
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